Paul R Rhomberg

JMI Laboratories, North Liberty, Iowa, United States

Are you Paul R Rhomberg?

Claim your profile

Publications (92)293.3 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study determined the performance of BD MAX StaphSR and the rate of MRSA with unrecognized SCC mec right-extremity junction (MREJ) region among 907 methicillin-resistant (MRSA) and 900 -susceptible S. aureus (MSSA) isolates. The rate of “ mecA/mecC drop-out" mutants was also evaluated. Only three MRSA (99.7% sensitivity; 904/907) were classified as MSSA by the BD MAX StaphSR assay, which were due to negative results for MREJ. Eight MSSA isolates (99.1% sensitivity; 892/900) were assigned as MRSA. However, six of these MSSA had the mecA gene confirmed by PCR and sequencing (99.8% sensitivity; 898/900). Overall, 7.1% (64/900) of MSSA showed results compatible with a mecA drop-out genotype.
    Journal of clinical microbiology 11/2015; DOI:10.1128/JCM.02047-15 · 3.99 Impact Factor

  • Helio S Sader · Paul R Rhomberg · David J Farrell · Ronald N Jones ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Gram-negative bacilli (n=15,377) were tested against colistin (polymyxin E) and polymyxin B by a commercial broth microdilution method (Sensititre®). Among Pseudomonas aeruginosa and Acinetobacter spp., colistin and polymyxin B MIC values were within ±1 doubling dilution for >99.0% of strains. Among Klebsiella spp. and Escherichia coli, 55.0 and 53.2% of strains displayed a colistin MIC 2-fold lower than polymyxin B, but polymyxin B was slightly more potent than colistin against strains with decreased susceptibility to either polymyxin.
    Diagnostic microbiology and infectious disease 09/2015; 83(4). DOI:10.1016/j.diagmicrobio.2015.08.013 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the antimicrobial activity of four polymyxin B components B1, B2, B3, and isoleucine (Ile)-B1 individually and in combination. B3 was the most active agent against all organisms tested except A. baumannii, for which Ile-B1 was most active. One combination met criteria for synergy, B3 + Ile-B1. No combinations exhibited antagonism. The dominant components of polymyxin B products (B1 and B2) were associated with the lowest probability of improved antibacterial activity when combined.
    Antimicrobial Agents and Chemotherapy 09/2015; 59(12). DOI:10.1128/AAC.01021-15 · 4.48 Impact Factor
  • M.A. Pfaller · P R Rhomberg · S.A. Messer · R N Jones · M. Castanheira ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The in vitro activities of isavuconazole, micafungin, and 8 comparator antifungal agents were determined for 1613 clinical isolates of fungi (1320 isolates of Candida spp., 155 of Aspergillus spp., 103 of non-Candida yeasts, and 35 non-Aspergillus molds) collected during a global survey conducted in 2013. The vast majority of the isolates of the 21 different species of Candida, with the exception of Candida glabrata (MIC90, 2μg/mL), Candida krusei (MIC90, 1μg/mL), and Candida guilliermondii (MIC90, 8μg/mL), were inhibited by ≤0.25μg/mL of isavuconazole. C. glabrata and C. krusei were largely inhibited by ≤1μg/mL of isavuconazole. Resistance to fluconazole was seen in 0.5% of Candida albicans isolates, 11.1% of C. glabrata isolates, 2.5% of Candida parapsilosis isolates, 4.5% of Candida tropicalis isolates, and 20.0% of C. guilliermondii isolates. Resistance to the echinocandins was restricted to C. glabrata (1.3-2.1%) and C. tropicalis (0.9-1.8%). All agents except for the echinocandins were active against 69 Cryptococcus neoformans isolates, and the triazoles, including isavuconazole, were active against the other yeasts. Both the mold active triazoles as well as the echinocandins were active against 155 Aspergillus spp. isolates belonging to 10 species/species complex. In general, there was low resistance levels to the available systemically active antifungal agents in a large, contemporary (2013), global collection of molecularly characterized yeasts and molds. Resistance to azoles and echinocandins was most prominent among isolates of C. glabrata, C. tropicalis, and C. guilliermondii. Copyright © 2015. Published by Elsevier Inc.
    Diagnostic microbiology and infectious disease 04/2015; 82(4). DOI:10.1016/j.diagmicrobio.2015.04.008 · 2.46 Impact Factor
  • Helio S Sader · Paul R Rhomberg · David J Farrell · Ronald N Jones ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Arbekacin is a broad-spectrum aminoglycoside licensed for systemic use in Japan and under clinical development as an inhalation solution in the United States (USA). We evaluated the occurrence of organisms isolated from pneumonias in USA hospitalized patients (PHP), including ventilator-associated pneumonia (VAP), and the in vitro activity of arbekacin. Organism frequency was evaluated from a collection of 2,203 bacterial isolates (339 from VAP) consecutively collected from 25 medical centers in 2012 through the SENTRY Antimicrobial Surveillance Program. Arbekacin activity was tested against 904 isolates from PHP collected in 2012 from 62 USA medical centers and 303 multidrug-resistant (MDR) organisms collected worldwide in 2009 and 2010 from various infection types. Susceptibility to arbekacin and comparator agents was evaluated by the reference broth microdilution method. The four most common organisms from PHP were Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella spp. and Enterobacter spp. The highest arbekacin MIC value among S. aureus from PHP (43% MRSA) was 4 μg/ml. Against P. aeruginosa from PHP, only one strain had an arbekacin MIC of >16 μg/ml (MIC50/90, 1/4 μg/ml), and susceptibility rates for gentamicin, tobramycin and amikacin were 88.0, 90.0 and 98.0%, respectively. Arbekacin (MIC50, 2 μg/ml) and tobramycin (MIC50, 4 μg/ml) were the most potent aminoglycosides tested against Acinetobacter baumannii. Against Enterobacteriaceae from PHP, arbekacin and gentamicin (MIC50/90, 0.25-1/1-8 μg/ml for both compounds) were generally more potent than tobramycin (MIC50/90, 0.25-2/1-32 μg/ml) and amikacin (MIC50/90, 1-2/2-32 μg/ml). Arbekacin also demonstrated potent in vitro activity against a worldwide collection of well characterized MDR Gram-negative and MRSA strains. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 03/2015; 59(6). DOI:10.1128/AAC.04839-14 · 4.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: S. aureus and coagulase-negative staphylococci (CoNS) are responsible for a wide variety of human infections. The investigational antibacterial Debio 1450 (previously AFN-1720), a prodrug of Debio 1452 (previously AFN-1252) specifically targets staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio 1452 inhibits FabI, an enzyme critical to fatty acid biosynthesis in staphylococci. The activity of Debio 1452 against CoNS, methicillin-susceptible (MSSA) and -resistant (MRSA) S. aureus, including significant clones, was determined. A globally diverse collection of 574 patient isolates from 35 countries was tested that included CoNS (6 species, 103 strains), MSSA (154), MRSA (163) and molecularly characterized strains (including spa typed MRSA clones; 154). Isolates were susceptibility tested by CLSI broth microdilution methods against Debio 1452 and 10 comparators. Susceptibility rates for comparators were determined using CLSI and EUCAST breakpoint criteria. All S. aureus and CoNS were inhibited by Debio 1452 concentrations of ≤0.12 and ≤0.5 μg/mL, respectively. MIC50 values for MSSA, MRSA and molecularly characterized-MRSA strains were 0.004 μg/mL and MIC90 values ranged from 0.008 - 0.03 μg/mL. MIC values were higher for CoNS isolates (MIC50/90, 0.015/0.12 μg/mL). Among S. aureus, resistance was common for erythromycin (61.6%), levofloxacin (49.0%), clindamycin (27.6%), tetracycline (15.7%) and trimethoprim-sulfamethoxazole (7.0%). Debio 1452 demonstrated potent activity against MSSA, MRSA and CoNS. Debio 1452 showed significantly greater activity overall (MIC50, 0.004 μg/mL) when compared to other agents tested against these staphylococcal species that included dominant MRSA clones and strains resistant to currently utilized antimicrobial agents. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 02/2015; 59(5). DOI:10.1128/AAC.05119-14 · 4.48 Impact Factor
  • Source
    Robert K Flamm · Paul R Rhomberg · Ronald N Jones · David J Farrell ·
    [Show abstract] [Hide abstract]
    ABSTRACT: RX-P873 is a novel antibiotic from the pyrrolocytosine series which exhibits high binding affinity for the bacterial ribosome and broad spectrum antibiotic properties. The pyrrolocytosines have shown in vitro activity against multi-drug resistant Gram-negative and Gram-positive strains of bacteria known to cause complicated urinary tract, skin, and lung infections, as well as sepsis. Enterobacteriaceae (657), P. aeruginosa (200) and Acinetobacter spp. (202) isolates from North America and Europe collected in 2012 as part of a worldwide surveillance program were tested in vitro by broth microdilution using Clinical and Laboratory Standards Institute (CLSI) methodology. RX-P873 (MIC90, 0.5 μg/mL) was >32 fold more active than ceftazidime and inhibited 97.1 and 99.5% of Enterobacteriaceae isolates at MIC of ≤1 and ≤4 μg/mL, respectively. There were only three isolates with MIC values >4 μg/mL (each were indole-positive Proteae). RX-P873 (MIC50/90, 2/4 μg/mL) was highly active against Pseudomonas aeruginosa isolates including isolates which were non-susceptible to ceftazidime or meropenem. RX-P873 was two-fold less active than tobramycin (MIC90, 2 μg/mL; 91.0% susceptible and colistin (MIC90, 2 μg/mL; 99.5% susceptible) and two-fold more potent than amikacin (MIC90, 8 μg/mL; 93.5% susceptible) and meropenem (MIC90, 8 μg/mL; 76.0% susceptible) against P. aeruginosa. RX-P873, the most active agent against Acinetobacter spp. (MIC90, 1 μg/mL) was two-fold more active than colistin (MIC90, 2 μg/mL; 97.0% susceptible and four-fold more active than tigecycline (MIC90, 4 μg/mL). This novel agent merits further exploration of its potential against multidrug resistant Gram-negative bacteria. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 02/2015; 59(4). DOI:10.1128/AAC.04840-14 · 4.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pexiganan, a 22-amino acid synthetic cationic peptide, is currently in Phase 3 clinical trials as a topical antimicrobial for the treatment of mild infections associated with diabetic foot ulcers. Bacterial isolates from the 2013 SENTRY Antimicrobial Surveillance Program designated as pathogens from diabetic foot infections (DFI) and Gram-negative and -positive pathogens from various infection types that harbored selected resistance mechanisms/phenotypes were tested against pexiganan in reference cation-adjusted Mueller-Hinton broth. The MIC50/90 against all organisms tested from DFI was 16/32 μg/mL. Echerichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter cloacae, Acinetobacter spp. and Pseudomonas aeruginosa MIC values ranged from 8-16 μg/mL. Pexiganan MIC values among Staphylococcus aureus (MRSA and MSSA), β-hemolytic streptococci and E. faecium ranged from 8-32 μg/mL. Pexiganan activity was not adversely affected for Enterobacteriaceae or P. aeruginosa that produced β-lactamases or resistance mechanisms to other commonly used antimicrobials. Decreased susceptibility to vancomycin did not affect pexiganan activity against S. aureus nor against E. faecium. E. faecalis appears to be intrinsically less susceptible to pexiganan (MIC, 32-256 μg/mL). The "all organism" MIC90 of 32 μg/mL for pexiganan in this study was >250-fold below the pexiganan concentration in the cream/delivery vehicle being developed for topical use. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 01/2015; 59(3). DOI:10.1128/AAC.04773-14 · 4.48 Impact Factor
  • M.A. Pfaller · P.R. Rhomberg · S.A. Messer · M. Castanheira ·
    [Show abstract] [Hide abstract]
    ABSTRACT: MGCD290, a Hos2 fungal histone deacetylase inhibitor showed modest activity when tested alone (MIC range, 0.12-4 μg/ml; MIC50/90, 0.5/4 μg/ml) against C. glabrata (n=15; 14 fks mutants; 5 also fluconazole-resistant), C. albicans (8 fks mutants; 2 also fluconazole-resistant), C. tropicalis (4 fks mutants), and C. krusei (3 fks mutants). However, MGCD290 showed synergy or partial synergy for 33.3, 30.1, 36.7 and 80.0% of the isolates when tested with anidulafungin, caspofungin, micafungin and fluconazole, respectively. Favorable interactions were achieved with low concentrations of MGCD290 (0.015 to 0.25 μg/ml) and categorical shifts were observed in 2 of 8 (25.0%) isolates of C. albicans and 2 of 3 (66.7%) isolates of C. krusei. In addition, 4 of the 5 (80.0%) fluconazole- resistant isolates of C. glabrata. MGCD290 exerts a distinctly favorable influence on the MICs of fluconazole and the echinocandins, resulting in conversion from resistance to susceptibility regardless of fks mutations.
    Diagnostic Microbiology and Infectious Disease 11/2014; 81(4). DOI:10.1016/j.diagmicrobio.2014.11.008 · 2.46 Impact Factor
  • Source
    Ronald N Jones · Nicole M Holliday · Paul R Rhomberg ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Tedizolid, a novel oxazolidinone antibacterial with potent activity against a wide range of Gram-positive pathogens, was recently approved by regulatory authorities for the treatment of acute bacterial skin and skin structure infections. A commercial broth microdilution device (Sensititre®, Thermo Fisher Scientific) was validated using 285 selected Gram-positive isolates, and was documented to have 100.0% essential and categorical agreement compared to reference MIC results, with excellent MIC endpoint reproducibility. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Journal of Clinical Microbiology 11/2014; 53(2). DOI:10.1128/JCM.02769-14 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The importance of antifungal surveillance was highlighted by the increasing resistance among certain species and breakthrough infections. We evaluated 1,846 fungal clinical isolates against 9 antifungals using CLSI reference broth microdilution methods (BMD). Additionally, 1,206 isolates were tested using polysorbate-80 (P-80). Methods: 1,846 isolates collected in 2013 (31 countries) were tested by CLSI BMD and interpretive criteria. Echinocandins (EC), amphotericin B (AMB) and fluconazole (FLC) were also tested using 0.002% P-80 supplemented broth. Isolates were identified using MALDI-TOF MS and/or DNA sequencing. Results: EC, AMB and FLC were active against common Candida spp. (Table). EC-resistance ranged from 0.0 to 2.8% (anidulafungin for C. glabrata [CGLA]). 11.9 and 11.6% of the CGLA and C. tropicalis were resistant to FLC, respectively. Two A. fumigatus displayed elevated MIC values for itraconazole (≥4 µg/mL). All C. neoformanshad MIC < epidemiological cutoff values for azoles. P-80 lowered the MIC values for EC for all species, but not for FLC. AMB MIC values were lower and ranges broader (0.03-0.5 µg/mL) when compared with reference BMD (0.5-2 µg/mL). Conclusion: EC and azoles were potent against yeasts and moulds. P-80 use broadened MIC ranges for AMB; however, differences in the growth patterns in RPMI + P-80, requirement for new QC ranges and a possible effect in cell growth reported previously in bacteria might be an impediment to the use of P-80 for antifungal BMD testing. Organism (no. tested [no. tested with P-80]) MIC/MEC50/90 for CLSI BMD (with P-80) Anidulafungin Caspofungin Amphotericin B Fluconazole C. albicans (712 [475]) 0.015/0.06 (≤0.008/≤0.008) 0.03/0.03 (≤0.008/≤0.008) 1/1 (0.06/0.12) 0.12/0.25 (0.25/0.25) C. glabrata (252 [156]) 0.06/0.12 (0.015/0.015) 0.03/0.06 (≤0.008/≤0.008) 1/1 (0.12/0.12) 8/64 (4/32) C. parapsilosis (215 [149]) 2/2 (1/2) 0.25/0.5 (0.06/0.06) 1/1 (0.12/0.25) 1/2 (1/4) C. tropicalis (155 [90]) 0.015/0.03 (≤0.008/≤0.008) 0.03/0.03 (≤0.008/≤0.008) 1/1 (0.06/0.12) 0.5/32 (0.5/1) C. krusei (49 [29]) 0.06/0.06 (0.03/0.03) 0.12/0.25 (0.03/0.03) 1/2 (0.25/0.25) 32/64 (32/64) A. fumigatus (142 [94]) ≤0.008/0.03 (≤0.008/≤0.008) 0.03/0.03 (≤0.008/≤0.008) 2/2 (0.25/0.5) -/-
    IDWeek 2014 Meeting of the Infectious Diseases Society of America; 10/2014
  • Source
    Steven L. Barriere · David J. Farrell · Paul R. Rhomberg · Ronald N. Jones ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Telavancin biological activity, determined by serum titers against a reference strain of Staphylococcus aureus, was maintained in the serum of subjects with severe renal impairment or end-stage renal disease (ESRD) suggesting that there is no apparent effect of renal function on in vitro activity of telavancin.
    Diagnostic Microbiology and Infectious Disease 09/2014; 80(4). DOI:10.1016/j.diagmicrobio.2014.09.002 · 2.46 Impact Factor
  • Source
    David J Farrell · Rodrigo E Mendes · Paul R Rhomberg · Ronald N Jones ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The reference broth microdilution (BMD) antimicrobial susceptibility testing method for telavancin was revised to include dimethyl sulfoxide as solvent and diluent for frozen-form panel preparation, following the CLSI recommendations for water-insoluble agents. Polysorbate-80 (P-80) was also added to the test media to minimize proven drug losses associated with binding to plastic surfaces. 462 Gram-positive isolates, including a challenge set of organisms with reduced susceptibility to comparator agents, were selected and tested using the revised method for telavancin, and the MIC results were compared with those tested by the previously established method and several Sensititre™ dry-form BMD panel formulations. The revised method provided MIC results two- to eight-fold lower than the previous method when tested against staphylococci and enterococci, resulting in MIC50 values of 0.03 - 0.06 μg/ml for staphylococci, and 0.03 and 0.12 μg/ml for E. faecalis and E. faecium. Less significant MIC decreases (one to two log2 dilution steps) were observed when testing streptococci in broth supplemented with blood, which showed similar MIC50 values. However, S. pneumoniae had MIC50 results of 0.008 and 0.03 μg/ml when tested by the revised and previous methods, respectively. Highest essential agreement rates (≥94.0%) were noted for one candidate dry-form panel formulation compared to the revised test. The revised BMD method provides lower MIC results for telavancin, especially when tested against staphylococci and enterococci. This is secondary to the use of DMSO for panel production and presence of P-80, which ensure the proper telavancin testing concentration and result in a more accurate MIC determination. Moreover, earlier studies where the previous method was applied underestimated the in vitro drug potency.
    Antimicrobial Agents and Chemotherapy 07/2014; 58(9). DOI:10.1128/AAC.03172-14 · 4.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The in vitro activity of isavuconazole and nine antifungal comparator agents was assessed using reference broth microdilution methods against 1,421 common and uncommon species of Candida from a 2012 global survey. Isolates were identified using CHROMagar, biochemical methods and sequencing of ITS and/or 28S regions. Candida spp. were classified as either susceptible or resistant and as wild type (WT) or non-WT using CLSI clinical breakpoints or epidemiological cutoff values, respectively, for the antifungal agents. Isolates included 1,421 organisms from 21 different species of Candida. Among Candida spp., resistance to all 10 tested antifungal agents was low (0.0-7.9 %). The vast majority of each species of Candida, with the exception of Candida glabrata, Candida krusei, and Candida guilliermondii (modal MICs of 0.5 µg/ml), were inhibited by ≤0.12 µg/ml of isavuconazole (99.0 %; range 94.3 % [Candida tropicalis] to 100.0 % [Candida lusitaniae and Candida dubliniensis]). C. glabrata, C. krusei, and C. guilliermondii were largely inhibited by ≤1 µg/ml of isavuconazole (89.7, 96.9 and 92.8 %, respectively). Decreased susceptibility to isavuconazole was most prominent with C. glabrata where the modal MIC for isavuconazole was 0.5 µg/ml for those strains that were SDD to fluconazole or WT to voriconazole, and was 4 µg/ml for those that were either resistant or non-WT to fluconazole or voriconazole, respectively. In conclusion, these data document the activity of isavuconazole and generally the low resistance levels to the available antifungal agents in a large, contemporary (2012), global collection of molecularly characterized species of Candida.
    Mycopathologia 06/2014; 178(1). DOI:10.1007/s11046-014-9772-2 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The antifungal broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) was compared with Clinical and Laboratory Standards Institute (CLSI) BMD method M27-A3 for amphotericin B, flucytosine, anidulafungin, caspofungin, micafungin, fluconazole, isavuconazole, itraconazole, posaconazole, and voriconazole susceptibility testing of 357 isolates of Candida. The isolates were selected from global surveillance collections to represent both wildtype (WT) and non-WT MIC results for the azoles (12% of fluconazole and voriconazole results were non-WT) and the echinocandins (6% of anidulafungin and micafungin results were non-WT). The study collection included 114 isolates of C. albicans, 73 of C. glabrata, 76 of C. parapsilosis, 60 of C. tropicalis, and 34 of C. krusei. The overall essential agreement (EA) between EUCAST and CLSI results ranged from 78.9% (posaconazole) to 99.6% (flucytosine). The categorical agreement (CA) between methods and species of Candida was assessed using previously determined CLSI epidemiological cutoff values (ECVs). The overall CA between methods was 95.0% with 2.5% very major (VM) and major (M) discrepancies. The CA was >93% for all antifungal agents with the exception of caspofungin (84.6%), where 10% of the results were categorized as non-WT by the EUCAST method and WT by the CLSI method. Problem areas with low EA or CA include testing of amphotericin B, anidulafungin, and isavuconazole against C. glabrata, itraconazole and posaconazole against most species, and caspofungin against C. parapsilosis, C. tropicalis, and C. krusei. We confirm high level EA and CA (>90%) between the two methods for testing fluconazole, voriconazole, and micafungin against all five species. The results indicate that the EUCAST and CLSI methods produce comparable results for testing the systemically active antifungal agents against the five most common species of Candida; however, there are several areas where additional steps toward harmonization are warranted.
    Diagnostic microbiology and infectious disease 06/2014; 79(2). DOI:10.1016/j.diagmicrobio.2014.03.004 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The amikacin fosfomycin inhalation system (AFIS), a combination of antibiotics administered with an in-line nebulizer delivery system, is being developed for adjunctive treatment of ventilator-associated pneumonia (VAP). The in vitro characterization of amikacin/fosfomycin (5:2) described herein included determining resistance selection rates for pathogens that are representative of those commonly associated with VAP (including multi-drug resistant strains), and evaluating interactions with antibiotics commonly used intravenously to treat VAP.Spontaneous amikacin/fosfomycin (5:2) resistance was not observed for most tested strains (n=10/14). Four strains had spontaneously resistant colonies (frequencies were 4.25 x 10(-8) to 3.47 x 10(-10)); colonies had 2- to 8-fold increases in amikacin/fosfomycin (5:2) minimum inhibitory concentrations (MIC) compared with the original strains. After 7 days of serial passage, resistance (>4-fold increase from baseline MIC) occurred in fewer strains (n=4/14) passaged in the presence of amikacin/fosfomycin (5:2), compared with either amikacin (n=7/14) or fosfomycin (n=12/14) alone.Interactions between amikacin/fosfomycin (5:2) and 10 comparator antibiotics in checkerboard testing against 30 different Gram-positive or Gram-negative bacterial strains were synergistic (fractional inhibitory concentration [FIC] index ≤ 0.5) for 6.7% (n=10/150) of tested combinations. No antagonism was observed. Synergy was confirmed by time-kill methodology for amikacin/fosfomycin (5:2) plus cefepime (against E. coli), aztreonam (P. aeruginosa), daptomycin (E. faecalis), and azithromycin (S. aureus). Amikacin/fosfomycin (5:2) was bactericidal at 4-fold the MIC for 7 strains tested.The reduced incidence of developing resistance to amikacin/fosfomycin (5:2), compared with amikacin or fosfomycin alone, and lack of negative interactions with commonly used intravenous antibiotics, further support the development of AFIS for the treatment of VAP.
    Antimicrobial Agents and Chemotherapy 04/2014; 58(7). DOI:10.1128/AAC.02779-13 · 4.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The amikacin fosfomycin inhalation system (AFIS) is a combination of 2 antibiotics and an in-line nebulizer delivery system that is being developed for adjunctive treatment of Gram-negative pneumonia in patients on mechanical ventilation. AFIS consists of a combination of amikacin and fosfomycin solutions in a 5:2 ratio (amikacin, 3 mL, 100 mg/mL and fosfomycin 3 mL, 40 mg/mL) and the PARI Investigational eFlow Inline System. In this antibiotic potentiation study, the antimicrobial activity of amikacin and fosfomycin, alone and in a 5:2 combination, were assessed against 62 Gram-negative pathogens from a worldwide antimicrobial surveillance collection (SENTRY). The 62 isolates of Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae had amikacin minimum inhibitory concentrations (MICs) of ≥ 32 μg/mL (Clinical and Laboratory Standards Institute [CLSI]: intermediate or resistant; European Committee on Antimicrobial Susceptibility Testing [EUCAST]: resistant). Each isolate was tested against amikacin (0.25 - 1024 μg/mL), fosfomycin (0.1 - 409.6 μg/mL), and amikacin/fosfomycin (5:2 ratio) using CLSI reference agar dilution methods.The median MIC values for amikacin and fosfomycin against the 62 isolates each decreased 2-fold with the amikacin/fosfomycin (5:2) combination, compared with either antibiotic alone. Interactions between amikacin and fosfomycin varied by isolate, and ranged from non-detectable to high potentiation. The amikacin/fosfomycin (5:2) combination reduced the amikacin concentration required to inhibit all 62 isolates from > 1024 to ≤ 256 μg/mL, and reduced the required fosfomycin concentration from 204.8 to 102.4 μg/mL. These results support continued development of the amikacin/fosfomycin combination for aerosolized administration, where high drug levels can be achieved.
    Antimicrobial Agents and Chemotherapy 04/2014; 58(7). DOI:10.1128/AAC.02780-13 · 4.48 Impact Factor
  • Source
    Helio S Sader · Paul R Rhomberg · Ronald N Jones ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The post-β-lactamase-inhibitor effect (PBLIE) of tazobactam combined with ceftolozane was evaluated by time-kill assays on two clinical Escherichia coli strains producing CTX-M-15 with or without TEM-1. The organisms were exposed (2 h) to 4 μg/ml/4 μg/ml of ceftolozane-tazobactam (4× MIC), 4 μg/ml of ceftolozane, and medium containing no drug, washed, and resuspended in medium alone or medium containing ceftolozane-tazobactam or ceftolozane. The PBLIE was determined as 1.3 to 2.1 h, and a postantibiotic effect was measured as 0.8 to 0.9 h.
    Antimicrobial Agents and Chemotherapy 01/2014; 58(4). DOI:10.1128/AAC.02398-13 · 4.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Isavuconazole is a new broad-spectrum triazole with a favorable pharmacokinetic and safety profile.METHODS: We report the MIC distributions for isavuconazole and 111 isolates of Candida (C. albicans [42 isolates], C. glabrata (25), C. parapsilosis (22), C. tropicalis (14), and C. krusei (8)) as determined by both CLSI and EUCAST broth microdilution (BMD) methods; also the comparative activity of isavuconazole, itraconazole, fluconazole, posaconazole, voriconazole and the three echinocandins was assessed against a recent (2011) global collection of 1,358 isolates of Candida spp., 101 of Aspergillus spp., 54 of non-Candida yeasts, and 21 of non-Aspergillus moulds as determined by CLSI BMD methods.RESULTS: The overall essential agreement (EA; ± two log2 dilutions) between the CLSI and EUCAST methods was 99.1% (EA ± 1 log 2 dilution, 90.1% [range 80.0-100.0%]). The activity of isavuconazole against the larger collection of Candida spp. and Aspergillus spp. was comparable to that of posaconazole and voriconazole: MIC90 values for these 3 triazoles against Candida spp. was 0.5, 1 and 0.25 μg/ml, respectively and against Aspergillus spp. was 2, 1 and 1 μg/ml, respectively. Isavuconazole showed good activity against Cryptococcus neoformans (MIC90, 0.12 μg/ml) and other non-Candida yeasts (MIC90, 1 μg/ml), but was less potent against non-Aspergillus moulds (MIC90, >8 μg/ml). MIC values for isavuconazole and three mucormycetes isolates were 4, 1 and 2 μg/ml, respectively, whereas all three were inhibited by 1 μg/ml of posaconazole.CONCLUSIONS: Isavuconazole demonstrates broad-spectrum activity against this global collection of opportunistic fungi and both CLSI and EUCAST methods may be used to test this agent against Candida with highly comparable results.
    Journal of clinical microbiology 06/2013; 51(8). DOI:10.1128/JCM.00863-13 · 3.99 Impact Factor

Publication Stats

2k Citations
293.30 Total Impact Points


  • 2001-2015
    • JMI Laboratories
      North Liberty, Iowa, United States
  • 2008-2011
    • Universidade Federal de São Paulo
      • School of Medicine
      San Paulo, São Paulo, Brazil
  • 2003
    • Tufts University
      Бостон, Georgia, United States
  • 2002
    • University of Iowa Children's Hospital
      Iowa City, Iowa, United States